tolterodine

(redirected from Detrol la)
Also found in: Dictionary.
Related to Detrol la: Overactive bladder

tolterodine

 [tol-ter´ah-dēn]
an antispasmodic agent used in treatment of bladder hyperactivity.

tolterodine

Pharmacologic class: Anticholinergic

Therapeutic class: Urinary tract antispasmodic

Pregnancy risk category C

Action

Competitively antagonizes muscarinic receptors, inhibiting bladder contractions and reducing urinary frequency

Availability

Capsules (extended-release): 2 mg, 4 mg

Tablets: 1 mg, 2 mg

Indications and dosages

Overactive bladder

Adults: 2 mg (immediate-release) P.O. b.i.d.; may decrease to 1 mg P.O. b.i.d. depending on response and tolerance. Or 4 mg (extended-release) P.O. daily; may decrease to 2 mg P.O. daily, depending on response.

Dosage adjustment

• Hepatic impairment or disease
• Renal impairment
• Concurrent use of potent CYP3A4 inhibitors

Contraindications

• Hypersensitivity to drug, its components, or to fesoterodine fumarate extended-release tablets
• Urinary or gastric retention
• Uncontrolled angle-closure glaucoma

Precautions

Use cautiously in:
• GI obstruction, significant bladder outflow obstruction, controlled angle-closure glaucoma, significant hepatic impairment, renal impairment
• pregnant or breastfeeding patients
• children (safety not established).

Administration

• Give with food to increase bioavailability.

Adverse reactions

CNS: headache, dizziness, vertigo, drowsiness, paresthesia, fatigue

CV: chest pain

EENT: vision abnormalities, xerophthalmia, pharyngitis

GI: diarrhea, constipation, abdominal pain, dyspepsia, dry mouth

GU: dysuria, urinary retention or frequency, urinary tract infection

Musculoskeletal: joint pain

Skin: dry skin

Other: weight gain, flulike symptoms, infection, anaphylaxis, angioedema

Interactions

Drug-drug. Clarithromycin, erythromycin, itraconazole, ketoconazole, miconazole: inhibited metabolism and increased effects of tolterodine

Drug-food. Any food: increased drug bioavailability

Patient monitoring

Monitor patient for anaphylaxis and angioedema with first or subsequent doses. If difficulty breathing, upper airway obstruction, or fall in blood pressure occurs, discontinue drug and promptly provide appropriate treatment.

Monitor patient for signs and symptoms of anticholinergic CNS effects, particularly after beginning treatment or increasing dosage. Consider dosage reduction or drug discontinuation if symptoms occur.
• Monitor bladder function.
• Assess blood pressure and stay alert for chest pain.
• Monitor neurologic status. Report paresthesia or visual impairment.

Patient teaching

• Tell patient to take with food.
• If patient takes extended-release form, instruct him not to chew or crush it.

Instruct patient how to recognize and immediately report signs and symptoms of anaphylaxis or angioedema.
• Caution patient not to drive or operate heavy machinery until drug's effects are known.
• Advise patient to use sugarless gum or hard candy to relieve dry mouth.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

tolterodine

/tol·ter·o·dine/ (tol-ter´ah-dēn) an antispasmodic used in the treatment of bladder hyperactivity.

tolterodine

a muscarinic receptor antagonist.
indications It is used to treat overactive bladder (frequency and urgency). It controls bladder incontinence by controlling contractions.
contraindications Factors that prohibit its use include known hypersensitivity, uncontrolled narrow-angle glaucoma, urinary retention, and gastric retention.
adverse effects Adverse effects include paresthesia, fatigue, headache, chest pain, hypertension, vision abnormalities, xerophthalmia, abdominal pain, constipation, dry mouth, dyspepsia, dysuria, urinary retention, urinary frequency, urinary tract infection, rash, pruritus, bronchitis, cough, pharyngitis, and upper respiratory infection. Common side effects include anxiety, dizziness, nausea, vomiting, and anorexia.

tolterodine

Detrol® Urology An agent used to manage overactive bladder Contraindications Urinary retention, gastric retention, narrow-angle glaucoma
References in periodicals archive ?
Tolterodine Tartrate ER Capsules are reportedly the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Detrol LA is the long-acting version of Detrol, already having generic competitors on the market.
M2 EQUITYBITES-January 6, 2014-Teva Pharmaceutical Industries Ltd reports availiblity of authorised generic Detrol LA in the US
M2 PHARMA-January 6, 2014-Teva Pharmaceutical Industries Ltd reports availiblity of authorised generic Detrol LA in the US
According to the company, it settled with Pfizer over its generic version of Detrol LA (tolterodine tartrate) extended-release capsules in the 2-mg and 4-mg strengths.
This release contains forward-looking information relating to the anticipated commencement of generic competition for Detrol LA in the U.
Tolterodine Detrol, Detrol LA, IR: 2 mg twice daily.
Healthcare company Pfizer Inc (NYSE:PFE) announced on Friday the settlement of its litigation against Mylan Inc and Mylan Pharmaceuticals Inc relating to Pfizer's patents covering Detrol LA (tolterodine tartrate) extended-release capsules.
The company added Toviaz reduced urge urinary incontinence (UUI) in patients with OAB who had a suboptimal response to its commonly prescribed treatment, Detrol LA (tolterodine tartrate extended release).
Currently, providers must choose between Ditropan XL, Detrol, and Detrol LA (approved by the Food and Drug Administration in December 2000) in the absence of a study that directly compares all 3 drugs.
Toviaz reduced urge urinary incontinence (UUI) in patients with OAB who had a suboptimal response (less than 50 percent reduction in UUI) to Detrol LA (tolterodine tartrate extended release), a commonly-prescribed treatment for the condition.
5 million settlement of a lawsuit alleging improper marketing of the prescription drugs Detrol and Detrol LA by defendant Pfizer, Inc.